Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of …
JH Schirmer, B Sanchez-Alamo, B Hellmich… - RMD open, 2023 - rmdopen.bmj.com
Objective To summarise and update evidence to inform the 2022 update of the EULAR
recommendations for the management of antineutrophil cytoplasm antibody-associated …
recommendations for the management of antineutrophil cytoplasm antibody-associated …
Diagnostic and therapeutic approach in ANCA-associated glomerulonephritis: a review on management strategies
A Molnár, P Studinger, N Ledó - Frontiers in Medicine, 2022 - frontiersin.org
Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is a destructive small
vessel vasculitis affecting multiple organs. Renal involvement often leads to end-stage renal …
vessel vasculitis affecting multiple organs. Renal involvement often leads to end-stage renal …
New Therapeutic Targets in Antineutrophil Cytoplasm Antibody–Associated Vasculitis
M Prendecki, SP McAdoo - Arthritis & Rheumatology, 2021 - Wiley Online Library
Antineutrophil cytoplasm antibody (ANCA)–associated vasculitis (AAV) is a rare systemic
autoimmune disease that is characterized by necrotizing inflammation of predominantly the …
autoimmune disease that is characterized by necrotizing inflammation of predominantly the …
Anti‐cytokine targeted therapies for ANCA‐associated vasculitis
MM Bala, TJ Malecka-Massalska… - Cochrane Database …, 2020 - cochranelibrary.com
Background Anti‐neutrophilic cytoplasmic antibodies (ANCA)‐associated vasculitis (AAV)
are a group of rare auto‐inflammatory diseases that affects mainly small vessels. AAV …
are a group of rare auto‐inflammatory diseases that affects mainly small vessels. AAV …
B cell therapy in ANCA-associated vasculitis
M McClure - 2022 - repository.cam.ac.uk
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare
autoimmune disease with a UK prevalence of 250 per million. The immunopathogenesis …
autoimmune disease with a UK prevalence of 250 per million. The immunopathogenesis …
Supplementary file 2: Evidence tables treatment GPA/MPA
JH Schirmer - rmdopen.bmj.com
Table of contents Page 1 Supplementary file 2: Evidence tables treatment GPA / MPA Page
1 of 188 Evidence Tables GPA / MPA Treatment Supplementary file 2 - GPA & MPA …
1 of 188 Evidence Tables GPA / MPA Treatment Supplementary file 2 - GPA & MPA …